JP2020518581A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518581A5
JP2020518581A5 JP2019559297A JP2019559297A JP2020518581A5 JP 2020518581 A5 JP2020518581 A5 JP 2020518581A5 JP 2019559297 A JP2019559297 A JP 2019559297A JP 2019559297 A JP2019559297 A JP 2019559297A JP 2020518581 A5 JP2020518581 A5 JP 2020518581A5
Authority
JP
Japan
Prior art keywords
composition
compound
disease
form according
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559297A
Other languages
English (en)
Japanese (ja)
Other versions
JP7098656B2 (ja
JP2020518581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030148 external-priority patent/WO2018204238A1/en
Publication of JP2020518581A publication Critical patent/JP2020518581A/ja
Publication of JP2020518581A5 publication Critical patent/JP2020518581A5/ja
Application granted granted Critical
Publication of JP7098656B2 publication Critical patent/JP7098656B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559297A 2017-05-01 2018-04-30 縮合イミダゾピペリジンjak阻害剤化合物 Expired - Fee Related JP7098656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492574P 2017-05-01 2017-05-01
US62/492,574 2017-05-01
PCT/US2018/030148 WO2018204238A1 (en) 2017-05-01 2018-04-30 Fused imidazo-piperidine jak inhibitor compound

Publications (3)

Publication Number Publication Date
JP2020518581A JP2020518581A (ja) 2020-06-25
JP2020518581A5 true JP2020518581A5 (https=) 2021-05-06
JP7098656B2 JP7098656B2 (ja) 2022-07-11

Family

ID=62165730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559297A Expired - Fee Related JP7098656B2 (ja) 2017-05-01 2018-04-30 縮合イミダゾピペリジンjak阻害剤化合物

Country Status (32)

Country Link
US (3) US10493077B2 (https=)
EP (1) EP3601283B1 (https=)
JP (1) JP7098656B2 (https=)
KR (1) KR102550225B1 (https=)
CN (1) CN110573508B (https=)
AR (1) AR111495A1 (https=)
AU (1) AU2018261593B2 (https=)
BR (1) BR112019022648A2 (https=)
CA (1) CA3056283A1 (https=)
CL (1) CL2019003086A1 (https=)
CO (1) CO2019011809A2 (https=)
CY (1) CY1125051T1 (https=)
DK (1) DK3601283T3 (https=)
EA (1) EA201992601A1 (https=)
ES (1) ES2908756T3 (https=)
HR (1) HRP20220330T1 (https=)
IL (1) IL270231B2 (https=)
LT (1) LT3601283T (https=)
MA (1) MA47970B1 (https=)
MD (1) MD3601283T2 (https=)
MX (1) MX388751B (https=)
NZ (1) NZ757570A (https=)
PH (1) PH12019502264A1 (https=)
PL (1) PL3601283T3 (https=)
PT (1) PT3601283T (https=)
RS (1) RS62995B1 (https=)
SG (1) SG11201908604YA (https=)
SI (1) SI3601283T1 (https=)
SM (1) SMT202200079T1 (https=)
TW (1) TWI760486B (https=)
UA (1) UA124478C2 (https=)
WO (1) WO2018204238A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CN113784713A (zh) * 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂
HUE067145T2 (hu) 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021185305A1 (zh) * 2020-03-18 2021-09-23 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特(成都)生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
EP4359402B1 (en) * 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak

Similar Documents

Publication Publication Date Title
JP2020518581A5 (https=)
HRP20220330T1 (hr) Kondenzirani imidazopiperidinski spoj, kao inhibitor jak
JP2023516640A5 (https=)
JP2019517463A5 (https=)
RU2020121150A (ru) Твердые формы ингибитора калликреина плазмы и его солей
US8580817B2 (en) 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA3025720A1 (en) Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors
JP2021504310A5 (https=)
JP2008514658A (ja) Bay43−9006トシレートの熱力学的に安定な形態
JP2018531982A5 (https=)
JP2020518582A5 (https=)
JP2021523918A5 (https=)
WO2019141179A1 (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
JP2019509268A5 (https=)
WO2003087086A2 (de) Substituierte indole und deren verwendung als 5ht-wiederaufnahme inhibitoren und als 5ht liganden
JP2021501151A5 (https=)
JP2017512786A5 (https=)
CN110776481B (zh) 一类双阳离子化合物及其制备方法和用途
JP2004307440A (ja) 2−アミノ‐1,3‐プロパンジオール誘導体とその付加塩
CN113412263A (zh) 氮杂双环取代的氧杂螺环衍生物、其制法与医药上的用途
CN106795152B (zh) 蛋白激酶抑制剂
KR20120098816A (ko) 메틸{4,6?디아미노?2?〔1?(2?플루오로벤질)?1h?피라졸로〔3,4?b〕피리딘?3?일〕피리미딘?5?일}카르바메이트의 신규한 다형체 형상
JP2022515376A5 (https=)
WO2021110010A1 (zh) 新型吡咯化合物
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib